Shield Therapeutics plc (AIM:STX)

Market Cap	76.44M
Revenue (ttm)	30.29M
Net Income (ttm)	-15.50M
Shares Out	1.06B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,121,316
Average Volume	5,497,831
Open	7.23
Previous Close	7.20
Day's Range	6.85 - 7.30
52-Week Range	2.10 - 9.40
Beta	1.27
RSI	45.93
Earnings Date	Sep 5, 2025

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 63
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.

Financial numbers in USD